It is with great pride that Pharmaceutical Executive presents the winners of this year’s APEX Awards. Decided by doctors, nurses and other health care professionals across the United States, this year’s ceremony included 30 industry leaders and globally recognized creative agencies.
This year’s winners were announced on November 13, 2024, at the New York Hilton Midtown in New York City.
The winners of the 2024 APEX Awards are as follows:
Aesthetics/Dermatology
Branded (FDA Regulated)
Company:
Sanofi & Regeneron
Agency:
Eversana InTouch
Campaign:
Eczema Skin Gallery
Disease Awareness
Company:
UCB
Agency:
Avant Healthcare
Campaign:
Make History (US HCP Campaign)
Cardiovascular
Branded (FDA Regulated)
Company:
AstraZeneca
Agency:
Addison Whitney
Campaign:
AmyLink / Amyloidosis Evidence Development Programme
Central Nervous System
Branded (FDA Regulated)
Company:
Lundbeck
Agency:
Eversana InTouch
Campaign:
Say "Yep" to Vypeti
Devices
Branded (FDA Regulated)
Company:
NeuroStar
Agency:
EvolveMKD
Campaign:
Breaking Barriers with Neurostar Depression Barometer
Disease Education/Awareness
Company:
Cerapedics Inc
Agency:
Scientific Global
Campaign:
FUSE: Fusion University for Surgical Excellence
Direct-to-Consumer
Branded (FDA Regulated)
Company:
Radius Health
Agency:
AbelsonTaylor
Campaign:
TYMLOS "Add to the Bone" Osteoporosis Consumer Campaign
Direct-to-Patient
Branded (FDA Regulated)
Company:
Arcutis
Agency:
AbelsonTaylor
Campaign:
The Cream That Can
Disease Education/Awareness
Company:
embecta
Agency:
Addison Whitney
Campaign:
From the Beginning | 2023 World Diabetes Day Campaign
Gastroenterology
Branded (FDA Regulated)
Company:
Nestle Health Science
Agency:
AbelsonTaylor
Campaign:
Toilet Monster
Immunology
Disease Education/Awareness
Company:
Pharvaris
Agency:
The Agency Network at MJH LifeSciences
Campaign:
Pharvaris DeflateHAE Awards Video
Men’s Health
Branded (FDA Regulated)
Company:
Sanofi
Agency:
Saatchi & Saatchi Wellness
Campaign:
Your Lucky Day and a Half
Metabolic
Disease Education/Awareness
Company:
Acella Pharmaceuticals
Agency:
Scientific Global
Campaign:
Treating Hypothyroidism
Branded (FDA Regulated)
Company:
Novo Nordisk
Agency:
ConcentricLife
Campaign:
Believe On
Oncology
Disease Education/Awareness
Company:
Elevar Therapeutics
Agency:
The Agency Network at MJH LifeSciences
Campaign:
Elevar uHCC Disease Awareness Campaign
Branded (FDA Regulated)
Company:
Manarini Stemline
Agency:
Biolumina
Campaign:
Picture What's Possible
Ophthalmology
Disease Education/Awareness
Company:
Kala Bio
Agency:
QBFox Healthcomm
Campaign:
Trail
Rare Disease
Branded (FDA Regulated)
Company:
Corcept Therapeutics
Agency:
Eversana InTouch
Campaign:
In the Clutches of Hypercortisolism
Disease Education/Awareness
Company:
Pharvaris
Agency:
The Agency Network at MJH LifeSciences
Campaign:
Pharvaris DeflateHAE Awards Video
Respiratory
Branded (FDA Regulated)
Company:
Boehringer Ingelheim
Agency:
Confideo, LLC
Campaign:
OFEV Holographic Augmented Reality KOL Integrations
Surgery
Branded (FDA Regulated)
Company:
Vericel Corporation
Agency:
AbelsonTaylor
Campaign:
MACI: No Challenge, No Change
Disease Education/Awareness
Company:
Cerapedics Inc
Agency:
Scientific Global
Campaign:
FUSE: Fusion University for Surgical Excellence
Women’s Health
Branded (FDA Regulated)
Company:
Exeltis USA
Agency:
Spark Growth
Campaign:
#LetsLoveEveryBody
Key Findings of the NIAGARA and HIMALAYA Trials
November 8th 2024In this episode of the Pharmaceutical Executive podcast, Shubh Goel, head of immuno-oncology, gastrointestinal tumors, US oncology business unit, AstraZeneca, discusses the findings of the NIAGARA trial in bladder cancer and the significance of the five-year overall survival data from the HIMALAYA trial, particularly the long-term efficacy of the STRIDE regimen for unresectable liver cancer.
Fake Weight Loss Drugs: Growing Threat to Consumer Health
October 25th 2024In this episode of the Pharmaceutical Executive podcast, UpScriptHealth's Peter Ax, Founder and CEO, and George Jones, Chief Operations Officer, discuss the issue of counterfeit weight loss drugs, the potential health risks associated with them, increasing access to legitimate weight loss medications and more.
Johnson & Johnson Seeks FDA Approval for Subcutaneous Tremfya Regimen for Ulcerative Colitis
November 22nd 2024Johnson & Johnson has submitted a supplemental Biologics License Application to the FDA for a subcutaneous induction regimen of Tremfya for adults with moderately to severely active ulcerative colitis based on positive Phase III ASTRO trial results.